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Background: Beyond cognitive decline, Alzheimer’s disease (AD) is characterized by numerous neuropathological
changes in the brain. Although animal models generally do not fully reflect the broad spectrum of disease-specific
alterations, the APPSL mouse model is well known to display early plaque formation and to exhibit spatial learning and
memory deficits. However, important neuropathological features, such as neuroinflammation and lipid peroxidation,
and their progression over age, have not yet been described in this AD mouse model.
Methods: Hippocampal and neocortical tissues of APPSL mice at different ages were evaluated. One hemisphere from
each mouse was examined for micro- and astrogliosis as well as concomitant plaque load. The other hemisphere was
evaluated for lipid peroxidation (quantified by a thiobarbituric acid reactive substances (TBARS) assay), changes in Aβ
abundance (Aβ38, Aβ40 and Aβ42 analyses), as well as determination of aggregated Aβ content (Amorfix A4 assay).
Finally, correlation analyses were performed to illustrate the time-dependent correlation between neuroinflammation
and Aβ load (soluble, insoluble, fibrils), or lipid peroxidation, respectively.
Results: As is consistent with previous findings, neuroinflammation starts early and shows strong progression over age
in the APPSL mouse model. An analyses of concomitant Aβ load and plaque deposition revealed a similar progression,
and high correlations between neuroinflammation markers and soluble or insoluble Aβ or fibrillar amyloid plaque
loads were observed. Lipid peroxidation, as measured by TBARS levels, correlates well with neuroinflammation in
the neocortex but not the hippocampus. The hippocampal lipid peroxidation correlated strongly with the
increase of LOC positive fiber load, whereas neocortical TBARS levels were unrelated to amyloidosis.
Conclusions: These data illustrate for the first time the progression of major AD related neuropathological
features other than plaque load in the APPSL mouse model. Specifically, we demonstrate that microgliosis and
astrocytosis are prominent aspects of this AD mouse model. The strong correlation of neuroinflammation with
amyloid burden and lipid peroxidation underlines the importance of these pathological factors for the
development of AD. The new finding of a different relation of lipid peroxidation in the hippocampus and
neocortical regions show that the model might contribute to the understanding of complex pathological
mechanisms and their interplay in AD.
Keywords: Aβ peptides, Aβ oligomers, Microgliosis, Astrocytosis, Lipid peroxidation, Correlation analysis,
Transgenic mice, APPSL* Correspondence: Birgit.hutter-paier@qps.com
1QPS-Austria GmbH, Parkring 12, 8074 Grambach, Austria
Full list of author information is available at the end of the article
© 2014 Löffler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Löffler et al. Journal of Neuroinflammation 2014, 11:84 Page 2 of 13
http://www.jneuroinflammation.com/content/11/1/84Background
Alzheimer’s disease (AD) is characterized by various
neuropathological events including amyloid plaques, oxi-
dative stress, and neuroinflammation. Dysregulated amyl-
oid precursor protein (APP) metabolism and resulting Aβ
generation seem to be central and early events in the dis-
ease [1]. Enhanced production of Aβ40 and Aβ42 trigger
the onset of several pathological changes, in particular
neuroinflammation. Activated microglia and reactive as-
trocytes represent the pivotal pathological hallmarks of
neuroinflammation. Microgliosis is well known to be acti-
vated by Aβ, Aβ fibrils, and Aβ oligomers and occurs early
in AD [2-5]. Intriguingly, early microgliosis promotes Aβ
clearance by protofibrillar Aβ phagocytosis [6,7], whereas
chronic microgliosis seems to promote Aβ accumulation
and subsequent neurodegeneration [6]. Astrogliosis, simi-
lar to microgliosis, can be caused by Aβ fibrils or oligo-
mers [8,9]. Transplanted murine adult and neonatal
astrocytes are able to internalize and degrade aggregated
human Aβ in the hippocampi of APP transgenic mice,
and can thus serve as active Aβ clearing cells [10]. In con-
trast, it has been shown that cytokines and Aβ42 promote
endogenous Aβ production in astrocytes [11]. Since the
quantity of astrocytes exceeds that of neurons in the brain,
activated astrocytes may consequently represent a signifi-
cant source of Aβ during the neuroinflammatory pro-
cesses [11]. Taken together, the current data indicate that
reactive microglia and activated astrocytes possess both
neuroprotective as well as neurodegenerative properties,
the latter especially in the chronic manifestation of AD.
Neuroinflammation promotes not only further Aβ ex-
pression but also oxidative stress. However, it is still
under debate whether oxidative stress is a consequence
of neurodegeneration [12]. Moreover, co-occurrence of
neuroinflammation and oxidative stress markers leads
to enhanced Aβ generation [13], thus closing the circuit
between reciprocal interferences of neuropathological
changes in AD.
Dysregulated APP metabolism can be triggered by mu-
tations in different genes [14], such as the Swedish
(K670N/M671L) [15] and London mutations (V717I)
within the APP gene [16]. In humans the Swedish muta-
tion causes a classic AD-like neuropathology, including
amyloid plaque load, neurite dystrophy, neuronal loss,
neuroinflammation, oxidative stress [17], and cognitive
decline [18]. The London mutation, on the other hand,
modifies the γ-secretase cleavage site and therefore shifts
amyloid secretion towards a relative increase of Aβ42
[19], resulting in early memory deficits and impaired
shifting abilities in humans [20]. The combination of
both mutations leads not only to increased Aβ plaque
pathology, but also to a strong and progressive decline
of cognitive and social abilities in mice [21,22]. So far,
several distinct neuropathological features of APPSLmice that neuronally express human APP with both the
Swedish and London mutations have not yet been de-
scribed, although this murine model has been exten-
sively used in neuropharmacology during the last decade
([23], review). Accordingly, we analyzed levels of soluble
and insoluble Aβ species, aggregated Aβ, fibrillar Aβ,
and oxidative stress markers. As a main goal, concomi-
tant hallmarks for astrocytosis (GFAP) and microgliosis
(CD11b), both indicators of neuroinflammation, were
quantified in the hippocampus and neocortex of APPSL
mice. Correlational analyses comparing neuroinflamma-
tion markers with Aβ levels as well as fibrillar Aβ and
levels of lipid peroxidation during disease progression
were performed in this murine AD model.
Methods
Animals
APPSL transgenic mice express APP751 with Swedish
(K670N/M671L) and London (V717I) mutations. These
mice feature characteristics of other already published
APP Swedish and London mouse models [21,24], but
are bred heterozygously on a pure C57BL/6 background
at QPS-Austria. Non-transgenic littermates (ntg) served
as the control for all experiments. A balanced number of
male and female animals were used and housed in indi-
vidually ventilated cages under a 12 hour light and dark
cycle. Standard rodent chow (Altromin™ Lage, Germany)
and normal tap water were available to the animals ad
libitum. Room temperature and humidity were kept at
approximately 24°C and between 40 and 70%, respect-
ively. Mice of different ages (between 1 and 12 months)
were selected for measurements; actual numbers are
given in the figure legends. Animal studies conformed to
the Austrian guidelines for the care and use of laboratory
animals and were approved by the Styrian Government,
Austria (FA10A-78Jo-71-2010).
Tissue sampling
Animals were deeply sedated by standard inhalation
anesthesia and transcardially perfused with 0.9% NaCl.
Brains were carefully removed and hemisected. The left
hemispheres were further dissected into the neocortex
and hippocampus, immediately shock frozen on dry ice
and stored at -80°C for biochemistry. The right hemi-
spheres were immersion fixed in 4% paraformaldehyde/
PBS (pH 7.4) at room temperature for 1 hour, cryo-
conserved in 15% sucrose solution until sunk and shock
frozen in liquid isopentane. Tissues were stored at −80°C
until used for histological analyses.
Tissue homogenization and protein extraction
Frozen tissue samples were weighed and a tissue
homogenization buffer (THB) (250 mM Sucrose, 1 mM
EDTA, 1 mM EGTA, 20 mM Tris pH 7.4) including
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was added, 1 ml THB per 100 mg of cortical tissue and
2.5 ml per 100 mg of hippocampal tissue. The tissue was
homogenized with a tissue ruptor (Qiagen, Hilden, Germany)
for 20 seconds at 33,000 rpm.
For the extraction of soluble Aβ peptides (‘aqueous-
soluble’ fraction), 100 μl of the THB homogenate was
mixed with 100 μl diethylamine (DEA) solution (0.4%
DEA, 100 mM NaCl). The mixture was spun for 1 hour
at 74,200 × g [m/s2] at 4°C. 170 μl of the supernatant
was transferred to a 1.5 ml Eppendorf tube and neutral-
ized with 17 μl 0.5 M Tris, at a pH 6.8.
For the extraction of insoluble Aβ peptides (’formic
acid soluble’ fraction), 100 μl of the THB homogenate
was mixed with 220 μl cold formic acid (FA) and soni-
cated for 1 minute on ice. Following this, 300 μl of the
solution was transferred to a tube and spun for 1 hour
at 74,200 × g [m/s2] at 4°C. Thereafter, 210 μl of the
supernatant was placed into a fresh tube, using a pipette,
and mixed with 4 ml formic acid (FA) neutralization so-
lution (1 M Tris, 0.5 M Na2HPO4, 0.05% NaN3).
Measurement of Aβ concentrations
Samples were analyzed for Aβ38, Aβ40 and Aβ42 with the
MSD™ 96-well MULTI-SPOT™ 4G8 Abeta Triplex Assay
(Meso Scale Discovery, Rockville, Maryland, United States)
detecting human and rodent Aβ species. The assay was
performed according to the manual. Plates were analyzed
on the Sector Imager 2400 (MesoScale Diagnostics™,
Rockville, Maryland, United States).
Measurement of lipid peroxidation -TBARS assay
In order to measure the lipid peroxidation, 50 μl of the
THB homogenates and 50 μl of 5% sodium dodecyl sul-
fate (SDS) solution, including 1 × protease inhibitor as
well as 5 mM of 1 × butylhydroxytoluene (BHT) solution,
were mixed and sonicated for 5 seconds. Malondialdehyde
(MDA) served as the standard at final concentrations
between 1 and 20 μM in 1:1 (v/v) mixtures of THB and
5% SDS. The thiobarbituric acid reactive species assay
(TBARS-assay) was started by adding 55 μl of 1.33% TBA
and 95 μl of 20% acetic acid (pH 3.5) to 100 μl of the pre-
pared samples or standards. After 1 hour of incubation at
95°C, 250 μl of n-butanol and pyridine mixture (15:1 v/v)
was added and gently mixed by inverting the tubes. After
centrifugation for 10 minutes at 4000 × g [m/s2], 200 μl of
the upper organic phase was transferred to 96-well plates
and absorbance was measured at 535 nm with a μQuant
plate photometer (BioTek Instruments Inc., Winooski,
Vermont, United States). It has to be mentioned that the
TBARS assay not only detects MDA, but reacts with other
species, including non-lipid derived MDA or lipid-derived
non-MDA substances. To differentiate these species, other
supportive analyses would be needed. However, thesetypes of analyses would go beyond the intention of this
study to show the most common read-out for lipid peroxi-
dation and necessitate a different basic setup.
Aggregated Aβ quantification
Hippocampal and cortical homogenates were analyzed
with the Amorfix Aggregated Aβ Assay (A4). In short,
samples were diluted in an assay buffer (phosphate buf-
fer, 1:100 for hippocampal samples, 1:1000 for neocortex
samples) and enriched on the A4 matrix to allow the
separation of Aβ monomers (flow-through) and Aβ ag-
gregates (matrix-bound). After the enrichment process,
samples were eluted from the A4 matrix and aggregated
Aβ was dissociated into monomers. After incubation
with a human-specific N-terminal Aβ antibody coupled to
Europium™ beads (Amorfix, Mississauga, Ontario, Canada)
followed by incubation with C-terminal Aβ antibodies
(recognizing Aβ40 and 42) coupled to magnetic beads,
time-resolved fluorescence was used to determine levels
of human-aggregated Aβ species in each sample.
Immunohistochemistry
Frozen brain hemispheres were sagittally cut. A system-
atic uniform random set of five sagittally cut 10-μm-
thick mounted sections from five different medio-lateral
levels (L2, L4, L6, L8 and L11, see Additional file 1 for sec-
tioning protocol) per animal were labeled with the follow-
ing primary antibodies: LOC recognizing amyloid fibrils
and fibrillar oligomers, but not monomers (AB2287; 1:500
Millipore, Billerica, Massachusetts, United States), GFAP
(Z0334; 1:500 Dako, Vienna, Austria) for reactive astrocytes
and CD11b (MCA711;1:1000 AbDSerotec, Puchheim,
Germany) for activated microglia. Binding was visual-
ized using highly cross-absorbed Cy secondary anti-
bodies (Cy2, 3 and 5; 1:500 Dianova, Hamburg, Germany).
Whole slices were imaged on a Zeiss Z1 Axio Imager
(Zeiss, Vienna, Austria) using an apochromat 10 × lens,
narrow band filter sets fitting to the dyes, and an AxioCam
MRm black and white camera (Zeiss, Vienna Austria) with
1 × opto-coupler. After delineation of the hippocampal
and neocortical regions (Additional file 2 for region
definition), stainings were quantified in automated rater
independent procedures with Image-Pro™ Plus (Media-
Cybernetics, Rockville, Maryland, United States), taking
into account the individual size of the area of interest
in the slice.
Immunoreactive (IR) objects were detected above an
intensity threshold based on 8-bit 256 grey levels, which
was adaptive for LOC and GFAP IR (mean signal + 1.2 ×
standard deviation of mean signal) and constant for
CD11b detection. The level varied for the different label-
ings adjusted to the background fluorescence in the
channel. Furthermore, detected objects had to overcome
a minimal size of 7 (LOC), 30 (GFAP - excludes single
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excludes resting microglial labeling). The latter was
based on frequency distribution statistics showing a shift
towards activated over resting microglia at this size. Data
export was as an automated filing mean and sum signal,
as well as surface area percentage, object density, mean
objects size, and threshold levels together with the image
title. Region size did not differ among groups, excluding
methodological bias and atrophy in the scope of the nat-
ural variance and used number (Additional file 3).
Statistics
Data analysis and graphs were created in GraphPad Prism™
4.03 (GraphPad Software Inc., California, United States).
Graphs include group means and standard error of the
mean (SEM). The significance level was set at P < 0.05.
Group means were compared using a one-way analysis
of variance (ANOVA) with a subsequent Newman-Keuls
post hoc comparison test, or a two-way ANOVA and a
Bonferroni’s multiple comparison test. Exact sample num-
bers are given in the figure legends. For histological mea-
surements, the values of the five slices per animal were
averaged to the individual mean. Group means were
calculated by averaging the individual means.
Results
Aβ levels in APPSL mice increase over age in cortical and
hippocampal samples
Aβ38, Aβ40 and Aβ42 levels in soluble (DEA) and insol-


















































































Figure 1 Aβ concentrations in hippocampal brain homogenates of AP
and Aβ42 (C, F) concentrations are shown in pg/mg hippocampal homog
and 12-month-old APPSL mice in comparison to non-transgenic littermates
Bonferroni’s post hoc test. * significances between genotypes+ significances
6-month-old APPSL and non-transgenic littermates as analyzed by Fisher’s leas
beta: Aβ, diethyl amine: DEA, formic acid: FA, analysis of variance: ANOVA, Am
probability: P.and 12-month-old APPSL animals were analyzed using a
MesoScale Discovery™ 4G8 Abeta Triplex Assay. As ex-
pected, all Aβ levels were very low in non-transgenic
mice at 6 months and increased only moderately until
12 months of age (Figure 1A). In APPSL transgenic ani-
mals, all but Aβ38 levels increased significantly in the
soluble fraction between 6 and 9 months of age, with
the highest increase in the Aβ42 species (Figure 1B, C). In-
soluble Aβ38 and Aβ40 progressively increased with age,
resulting in levels of approximately 6000 pg/mg for
Aβ38 and 50,000 pg/mg for Aβ40 at 12 months of age
(Figure 1D, E). Interestingly, insoluble Aβ42 levels
reached a plateau at the age of 9 months, with levels
staying high at approximately 26,500 pg/mg at both 9
and 12 months of age (Figure 1F). A parallel progression
could be observed for the soluble peptides (Figure 1A-C),
though Aβ38, Aβ40 and Aβ42 levels were 17-, 45-, and
53-fold lower, respectively, compared to the insoluble Aβ
in the FA fraction (Figure 1D-F).
The analyses of cortical samples of APPSL mice re-
vealed a similar trend. However, soluble Aβ levels were
about 2-3-fold higher in the hippocampus than in the
neocortex. Insoluble Aβ levels on the other hand, were
almost as high in the neocortex as in the hippocampus
(Additional file 4).
Additional analyses of all Aβ data by Fisher’s least sig-
nificance test accounting for data with very strong pro-
gression, revealed a highly significant increase of soluble
Aβ38, Aβ40 and Aβ42 as well as insoluble Aβ40 and


















































PSL transgenic mice increase over age. Aβ38 (A, D); Aβ40 (B, E),
enates for soluble (DEA; A-C) and insoluble (FA; D-F) fractions of 6, 9,
. n = 10/group. All data were analyzed by two way ANOVA followed by
between age groups of APPSL transgenic mice.
# significances between
t significance test. *P <0.05; **P <0.01; ***P <0.001. Abbreviations: amyloid
yloid Precursor protein carrying the Swedish London mutation: APPSL,
Figure 2 Progressively increasing aggregated Aβ concentrations and plaque load in brain homogenates of APPSL transgenic mice.
A: Aggregated Aβ concentration in the hippocampus and neocortex of 1, 4, 6, and 12-month-old APPSL transgenic mice as analyzed by Amorfix
A4 assay. Data are shown as signal to noise (S/N) ratio, with N equal to the signal generated by buffer alone. Animals of the one month group
were between 1 and 3-months-old. 1 month: n = 7; 4 months: n = 5; 6 and 12 months: n = 11. Data were analyzed by two way ANOVA followed
by Bonferroni’s post hoc test. * significances between age groups of APPSL neocortical tissue. + significances between age groups of APPSL
hippocampal tissue. B: Quantification of LOC as immunoreactive area in percent in the hippocampus and neocortex of 6, 9, and 12-month-old
APPSL transgenic mice. n = 6/group. C: Representative images of sagittal sections of 6, 9, and 12-month-old APPSL transgenic mice labeled with
LOC. Inlets show magnifications of neocortical and hippocampal brain regions. Data were analyzed by one way ANOVA followed by Bonferroni’s
post hoc test. *P <0.05; **P <0.01; ***P <0.001. Abbreviations: amyloid beta: Aβ, analysis of variance: ANOVA, Amyloid Precursor protein carrying
the Swedish London mutation: APPSL, probability: P, neocortex: Cx, hippocampus: HC.
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strates that six-month-old APPSL mice already exhibit sig-
nificantly increased Aβ levels compared to non-transgenic
littermates.
Assessment of aggregated Aβ and fibrillar Aβ plaque load
To evaluate the relative distribution of aggregated Aβ in
the hippocampus and neocortex of 1, 4, 6, and 12-
month-old APPSL mice, analyses were performed using
the Amorfix A4 assay. The results showed a significant
increase in levels of aggregated Aβ with age. The finding
that graphs of the hippocampus and neocortex are
nearly superimposable (Figure 2A) suggests a uniform
distribution of aggregated Aβ in these two brain regions.
The brain fibrillar Aβ content was investigated by the
quantification of LOC immunoreactivity in the hippo-
campus and neocortex of 6, 9, and 12-month-old trans-
genic APPSL mice. LOC is specific to a fibrillar amyloid
structure and binds to mature and immature amyloid de-
positions. LOC labeling is more sensitive at measuring
total plaque burden compared to classical plaque markers
(6E10, 4G8, Congo red, and so on), thus a 2.5% IR area
was detected at the young age of 6 months. Remarkably,
our data also revealed high absolute levels of fibrillar
Aβ and a significant and profound progression between
6 and 12-month-old APPSL animals in both brain re-
gions, and in the cortex also between 6 and 9 months
(Figure 2B). No significant difference was measured be-
tween the hippocampus and neocortex. Representative
images of LOC IR amyloid load and its spread over age
are shown in Figure 2C. The absent LOC labeling in
non-transgenic littermates is shown in Additional file 5.
Oxidative stress markers increase over age in APPSL mice
Oxidative stress measured by the lipid peroxidation indi-
cator TBARS (TBARS assay) at the age of 4, 6, 9, and
12 months is shown for the hippocampus (Figure 3A)A Hippocampus




























Figure 3 Progression of oxidative stress in the hippocampus and neo
shown as TBARS levels per mg protein in the hippocampus (A) and neoco
were analyzed by two way ANOVA followed by Bonferroni’s post hoc test. *
of APPSL transgenic mice. *P <0.05; **P <0.01; ***P <0.001. Abbreviations: TBAR
Amyloid Precursor protein carrying the Swedish London mutation: APPSL, proand the neocortex (Figure 3B) of APPSL transgenic and
non-transgenic littermates. TBARS levels increased
moderately from 4 to 12 months in non-transgenic lit-
termates. The relative increase was more pronounced in
the hippocampal compared to cortical specimens. The
increase in the neocortex between 4 and 12-month-old
non-transgenic mice was significant. In APPSL transgenic
animals however, a profound increase in oxidative stress
was observed between 6 and 9 months with essentially no
further increase up to 12 months. This led to genotype-
dependent significantly elevated TBARS levels in APPSL
transgenic animals at 9 and 12-months-old.
Micro- and astrogliosis profoundly increase over age in
APPSL mice
Histological quantification of CD11b staining in the
hippocampus and neocortex of 6, 9, and 12-month-old
APPSL mice revealed significant microglia activation at
all age groups compared to non-transgenic littermates
(Figure 4A, B). Most notably, the increase is linearly pro-
gressive over age (Figure 4A, B). Cortical astrogliosis
was genotype-dependently increased at 9 and 12 months,
but not at 6 months. Astrogliosis levels increased signifi-
cantly in APPSL mice between 6 and 9 months and
reached a plateau between 9 and 12 months (Figure 4D).
In the hippocampus the amount of GFAP immunoreac-
tivity detected in both APPSL transgenic and non-
transgenic littermates were similar and unchanged over
age (Figure 4C). Representative images of CD11b and
GFAP double-labeling of 6, 9, and 12-month-old APPSL
mice showed the age-related pronounced increase in
neuroinflammation in the neocortex (Figure 4E).
Correlations between Aβ levels, gliosis and oxidative stress
Linear regression analyses (Pearson’s correlation) revealed
a large number of significant variable dependencies. Ana-
lyses showed strong correlations in the neocortex betweenB
Cortex



























cortex of APPSL transgenic mice over age. Lipid peroxidation is
rtex (B) of 4, 6, 9, and 12-month-old APPSL mice. n = 18/group. All data
significances between genotypes. + significances between age groups
S: thiobarbituric acid reactive substances, analysis of variance: ANOVA,
bability: P.
Figure 4 Progression of microglia activation and reactive astrogliosis in different brain areas of APPSL transgenic mice over age.
Activated microglia (CD11b staining; A, B) and reactive astrocytes (GFAP staining; C, D) in the hippocampus (A, C) and neocortex (B, D) of 6, 9,
and 12-month-old APPSL mice are shown as the percentage of immunoreactive area (IR). n = 6/group. E: Representative images of CD11b (green)
and GFAP (red) immunofluorescent double-labeling counterstained with DAPI in the subiculum of 6, 9, and 12-month-old APPSL mice and a
12-month-old non-transgenic littermate. Note the absence of gliosis in the non-transgenic littermate, while micro- and astroglia typically progressively
and concomitantly circumvent amyloid plaques in APPSL mice at higher frequency with the increase of local plaque load. All data were analyzed by
two way ANOVA followed by Bonferroni’s post hoc test. * significances between genotypes. + significances between age groups of APPSL transgenic
mice. *P <0.05; **P <0.01; ***P <0.001. Scale bar: 100 μm. Abbreviations: neocortex: Ctx, corpus callosum: cc, subiculum: Sub., glial fibrillary
acidic protein: GFAP, DAPI: 4′,6-Diamidin-2-phenylindol, analysis of variance: ANOVA, Amyloid Precursor protein carrying the Swedish London
mutation: APPSL, probability: P.
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(GFAP levels) and levels of Aβ (Figure 5A). For example
the correlations between astrocytosis or microgliosis andsoluble Aβ42 (r = 0.85, r = 0.82, respectively), insoluble
Aβ38 (r = 0.9, r = 0.75, respectively) and Aβ40 (r = 0.86
(Figure 5B), r = 0.72 (Figure 5C), respectively) were highly
Figure 5 Correlation analyses of neuropathological features of APPSL mice of all age groups. (A) Correlation between neuroinflammation
markers GFAP or CD11b and soluble or insoluble Aβ levels, fibrillar Aβ (LOC) or lipid peroxidation in the neocortex or hippocampus of APPSL mice over
age. Pearson’s correlation coefficient (r) and P value (*P <0.05; **P <0.01; ***P <0.001) are shown. Representative graphs of correlations between GFAP
(B) or CD11b (C) and Aβ40 in the cortex over age are given. Abbreviations: glial fibrillary acidic protein: GFAP, amyloid beta: Aβ, analysis of variance:
ANOVA, Amyloid Precursor protein carrying the Swedish London mutation: APPSL, probability: P.
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tosis also correlated significantly with both fibrillar Aβ
levels and lipid peroxidation levels. In contrast, although
hippocampal correlation coefficients were comparably high
for activated microglia compared to levels of Aβ and fibril-
lar Aβ, no significant correlations were found between hip-
pocampal microgliosis and lipid peroxidation, or between
hippocampal astrogliosis and any markers.
Progression of pathological hallmarks of APPSL mice
Data generated in this study were expressed as relative
percent change compared to age-matched non-transgenic
littermates, whereas the six-month-old non-transgenic
group was plotted as a reference for the changes observed
for the first correlatively investigated age. Figure 6 thusallows a comparison of events in a timely manner, and of
the degree of change within each marker. At first sight the
dynamics are notably different for the neocortex and the
hippocampus.
In the neocortex, microglial activation increase to 25%,
while astrogliosis and amyloid fiber load rise to approxi-
mately 12% at the age of 6 months. Increased lipid peroxi-
dation cannot be observed at this age, thus it lags behind
early amyloid deposition and inflammatory events. How-
ever, increasing amyloid levels and neuroinflammation
towards 9 months of age are paralleled by an enormous
increase of TBARS levels, while microglial activation does
not follow with a strong change (Figure 6A).
In the hippocampus the profile is similar in regards to































normalized % change (to age-matched nTg)
A B
Figure 6 Progression of pathological hallmarks in APPSL mice over age. Graphs represent percent change of markers normalized to the
values of age-matched non-transgenic littermates. Six-month-old non-transgenic littermates serve as baseline to show the change at the onset
age. The maximum change during the investigated age span is set to 100%. Thus data display the dynamics of amyloid fiber load (LOC), activated
microgliosis (CD11b), astrogliosis (GFAP) and lipid peroxidation (TBARS) for the neocortex (A) and the hippocampus (B). Abbreviations: glial fibrillary
acidic protein: GFAP, thiobarbituric acid reactive substances: TBARS, amyloid beta: Aβ, Amyloid Precursor protein carrying the Swedish
London mutation: APPSL.
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crease together with LOC immunogenicity, without a
time lag and strikingly parallel in the extent. Just as in
the neocortex, lipid peroxidation is most prominent be-
tween 6 and 9 months of age, while again the microglial
activation lags behind in the phase of increasing TBARS
levels (Figure 6B). The concomitance of hippocampal
TBARS levels with amyloidosis can also be observed in
the correlation analyses. Whereas cortical TBARS levels
are never correlated with any LOC immunogenicity,
hippocampal TBARS levels significantly correlate with
cortical levels (r = 0.69, P = 0.0039), as well as the hippo-
campal LOC load (r = 0.74, P = 0.0013).
Discussion
The present study illustrates for the first time the pro-
gressive increase in AD-specific biochemical hallmarks
in APPSL mice, including profoundly increased soluble
and insoluble Aβ40 and Aβ42 levels, aggregated Aβ, fi-
brillar Aβ, lipid peroxidation, and astro- as well as
microgliosis in the hippocampus and neocortex up to an
age of 12 months. Correlation analyses revealed a highly
significant correlation between the severity of neuroin-
flammation and Aβ, fibrillar Aβ and lipid peroxidation
levels.
Several studies in the past have demonstrated that
Aβ40 and Aβ42 levels are elevated in the cortex of AD
patients. This increase is even detectable in questionable
dementia cases and correlates with the subsequently ob-
served progression of cognitive decline [25]. As such, in-
creasing Aβ40 and Aβ42 peptide concentrations in the
brain seem to be useful indicators of developing demen-
tia. When analyzing the different effects of soluble and
insoluble Aβ peptides in the brains of AD patients,
McLean et al. [26] identified soluble Aβ species as indi-
cators for the severity of the disease. Similar results wereobtained by Gong et al. [27] who unraveled the import-
ance of small, soluble Aβ oligomers for AD pathology,
suggesting that they might be appropriate targets for
therapeutic AD drugs [27]. In fact, vaccination and
immunization studies designed to reduce the Aβ peptide
burden have led to learning and memory improvements
in transgenic AD mice [28-30]. In contrast, the results
from McLean et al. implied that amyloid plaque load
serves only as a general marker of AD even under condi-
tions when its total concentration is very high [26].
However, post mortem amyloid plaque analysis in
humans is widely performed semi-quantitatively, which
has a high variance between sampling, protocols and
raters performing the assessments. These variable find-
ings add to the methodological complexity of AD diag-
nosis and correlation analyses.
From the correlation data presented in this study we
demonstrate that most measured variables increase in
parallel which makes it impossible to incriminate one
variable as the source, at least for the APPSL mouse
model. All analyzed variables, (aggregated Aβ, fibrillar
Aβ, soluble and insoluble Aβ species) significantly in-
creased over age and correlated with neuroinflammation
markers. This implies that all these variables simultan-
eously contribute to AD disease progression. Havas
et al. [21] previously analyzed the amyloid plaque load
and number of plaques in APP mice with Swedish and
London mutations, and observed the same progression
for classical plaque markers (6E10 and Thioflavin S).
Thus Aβ concentration, fibrillar Aβ and plaque load of
APPSL mice correspond to each other, as well as to cog-
nitive decline, from 6 months of age onwards [21].
To date, the significance of plaque load for AD is still
under debate. While several groups found the pattern of
amyloid plaques to be of limited relevance for the neuro-
pathological staging of AD [31-33], results from other
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counts of senile plaques in the hippocampus and cortex,
and memory function such as the Blessed test for Infor-
mation, Concentration, and Memory (BICM) in humans
[34]. Recent findings describing Aβ deposition as a very
slow process in humans, mostly occurring within the
preclinical stage, and reaching a plateau as AD pro-
gresses, contradict a good correlation with the progres-
sive memory decline in AD [35-37]. In contrast to this
slow disease progression over years in humans [38],
in vivo imaging of APP mice (Tg2576) has identified
plaque formation and maturation as a fast process, oc-
curring within weeks [38].
Microglial activation parallels Aβ plaque burden in AD
patients and is thus a characteristic feature of AD pro-
gression [39,40]. This is consistent with the data pre-
sented here, where Aβ and Aβ fibril load strongly
correlate with microgliosis. The modifiable nature of re-
active microgliosis in these mice was previously shown
by Imbimbo et al. [41] who treated the APPSL mice with
a γ-secretase modulator or ibuprofen as a positive con-
trol, resulting in a significant reduction of microglial in-
flammation [41]. Since corresponding correlation analyses
were not performed, memory improvement cannot be as-
sociated with the decreased plaque load or neuroinflam-
mation with certainty.
Beyond microgliosis, reactive astrocytes are the second
major component of neuroinflammation in AD. A previous
report demonstrated that affected patients present with a
significant increase in astrocytosis in their hippocampal
[42] and cortical areas [43] compared to non-demented pa-
tients. In our APPSL mouse model we observed a profound
increase only in neocortical but not in hippocampal react-
ive astrocyte levels up to an age of 12 months. This sug-
gests that our mouse model, at first glance, does not
exactly mimic the human phenotype. However, in both
humans and APPSL mice, Aβ plaques start to accumulate
in the neocortex and only afterwards spread into the
hippocampus. As such, it cannot be precluded that astro-
gliosis will be measurable in APPSL mice at time points
later than those evaluated in the current study.
Previous preclinical data demonstrated a successful
pharmacological intervention which reduced astrogliosis
in APPSL mice [44]. Treatment of these animals with a
cholesterol acyltransferase inhibitor caused, in addition
to a reduction of amyloid plaque load and insoluble
Aβ40 and Aβ42, a significant decrease in astrogliosis
[44], suggesting that neuroinflammation in APPSL mice
is a susceptible target for AD treatment.
The importance of neuroinflammation for the develop-
ment of AD pathology is still under debate since neuroin-
flammatory events are shown to promote Aβ clearance,
whereas chronic neuroinflammatory events seem to pro-
mote Aβ accumulation [6-11]. Since the data presentedhere point towards an Aβ expression followed by neu-
roinflammatory events, microglia activation might indeed
elevate Aβ clearance. If such an effect exists, it is not
measurable in our Aβ quantification, but might be hidden
due to extensive amyloid depositions. Other characteriza-
tions of AD mouse models are published that show pro-
inflammatory markers, as well as microgliosis, that seem
to be active even before amyloid pathology [45-48]. How-
ever, investigations such as Heneka’s et al. [46] lack
markers for early immature amyloid deposition (such as
LOC immunoreactive fibers) and focused on Aβ1-42
and Thioflavin S [46], which can typically be found in
the core of mature plaque depositions at late AD stages.
Others, such as the characterization by Abbas et al.
[47] or Janelsins et al. [48] similarly show neuroinflam-
mation markers to be increased in parallel or after Aβ
expression. Although there may be some exceptions,
for example Janelsins’ report of early inflammatory
changes preceding amyloid pathology in the 3 × Tg-AD
mouse model [48], the majority of studies demonstrate
parallels in the timing of pro-inflammatory events and
amyloid deposition [49]. In any case and independent of
probable differences between different animal models, the
start of amyloid deposition and gliosis is similar to
humans, closely correlated and the connection could be
instant and bidirectional [39,40,50,51].
The current understanding implies that oxidative
stress is a hallmark of AD and able to activate inflamma-
tory processes [12]. Oxidative damage is increased in pa-
tients with mild cognitive impairment (MCI) and early
AD, highlighted by increased protein carbonyls, MDA
[52], TBARS [53], and prolidase. Of particular interest is
the finding that in AD patients an increased total oxi-
dant status correlates negatively with results of the Mini
mental state examination (MMSE) [54]. Accordingly,
two additional publications on oxidative stress in MCI
and AD patients define oxidative damage as the earliest
events in AD development [55,56]. These data are fur-
ther supported by results of Nunomura et al. [57] who
analyzed the relationship between two oxidative damage
markers and histological and clinical variables in AD in-
dividuals. Their findings clearly identified the most se-
vere oxidative damage in early disease stages while
decreasing with increasing Aβ accumulation [57].
Our evaluation of lipid peroxidation as a marker for
oxidative stress in the neocortex of APPSL mice seem-
ingly contradicts hitherto findings in humans. Our data
revealed a pronounced increase in lipid peroxidation
[57], but lagging behind the significant amyloid depos-
ition and concomitant astro- and microgliosis in the cere-
bral cortex. In the hippocampus, on the other hand,
TBARS correlatively increased with LOC immunogenicity.
These findings suggest that regional differences may exist
which effect the biochemical reactions influencing lipid
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prominent role.
Tissue storage under nitrogen gas would protect sam-
ples from subsequent oxidative events but was not used
in this study. Thus, tissue storage might be a slight cav-
eat since artificial changes in oxidative damage from tis-
sue preparation might have occurred. However, since
tissues of all animals of this study were sampled and
stored in the same way, the potential change in oxidative
damage is relative.
A common and interesting finding in the hippocampus
and neocortex was the decreased microglia activation in
the phase of strong increase of lipid peroxidation be-
tween 6 and 9 months of age. Notably this relation could
shed light on a possible mechanism on how antioxidants
such as resveratrol [58] could, for example, act by in-
creasing microglial activation and enhanced microglia
clearance of amyloid deposits by altering oxidative stress.
Although, Capiralla et al. [59] as well as Solberg et al.
[60] recently showed rather lower microglial activity
which was parallel to decreased amyloid load [59,60],
Solberg further claimed low potential of the antioxida-
tive effect of resveratrol. The authors’ conclusion of
microglial deactivation might have been carried too far,
since both studies were evaluated after long treatment pe-
riods and not monitored during probably critical phases.
Furthermore, the disappearance of microglia around amyl-
oid plaques as measured by Capiralla et al. [59] might
rather argue for activation towards a macrophagic and
mobile M2 type, while the usual stickiness of microglia to
amyloid plaques could rather reflect the problematical
chronic inflammatory response and reduced amyloid
clearance ability. Microglia activity might thus be down
regulated in the study by Capiralla et al. simply due to the
fact that TBARS is increased, which would support
Solberg et al.’s finding of low antioxidant potential [59,60].
However, APPSL mice first start to present significant
cognitive deficits at the age of 6 months [61]. At this
age, animals already have highly increased Aβ levels,
neuroinflammation, and the appearance of lipid peroxi-
dation differs between brain regions. Therefore, it can be
concluded that lipid peroxidation in APPSL mouse brains
is not necessarily a prerequisite for the development of
cognitive deficits, but fits concomitantly to hippocampal
amyloid fiber deposition and hippocampal dependent
learning tasks. As a challenging question for the future,
it might be a rather consecutive event in the pathological
cascade in neocortical regions. A parallel of hippocampal
oxidative stress and symptomatic memory loss might
even explain why symptomatically normal subjects can
live with cortical amyloid load, while increased hippo-
campal oxidative stress could induce a seesaw of patho-
logical events leading to the severe memory deficits
observed.Conclusions
Inflammatory changes in the neocortex of APPSL mice
strongly correlate with levels of Aβ peptides, fibrillar Aβ,
LOC immunoreactive Aβ, and lipid peroxidation, reflect-
ing a strong interrelationship between all variables. Since
APPSL mice overexpress mutated APP, it is assumed that
Aβ overexpression is the initiating event in the patho-
logical cascade of AD specific hallmarks. Together with
previously published data on progressive cognitive de-
cline [21,22,61], the current study shows that APPSL
mice closely mimic the behavioral and neuropathological
profile of AD patients, and might help to further eluci-
date the complex association of pathological factors in
the disease.
Additional files
Additional file 1: Mediolateral sequence of sagittal sectioning
levels. Uniform, systematic random sets of ten sections per level
covering the neocortex and hippocampal formation were collected from 12
mediolateral levels. Drawings taken from ‘The Mouse Brain in Stereotactic
Coordinates’ by Paxinos and Franklin (2001, 2nd Edition). The sectioning
starts with a random section at approximately 0.24 lateral from midline and
extends uniformly and systematically throughout the whole hemisphere,
always retaining 10 and discarding 20 sections per level. Levels 2, 4, 6, 8 and
11 were labeled [62].
Additional file 2: Manual delineation of measured brain areas.
Anatomical figure taken from Paxinos & Franklin ‘The Mouse Brain
Atlas’ showing the delineations of the regions defined as ‘cortex’ and
‘hippocampus’. Note that the boundaries for the hippocampus include
the subiculum but exclude the white matter (fimbria) and that the
cortex was defined as the neocortex excluding the accessory olfactory
cortices, tubercle and amygdala and including the cingulate [62].
Additional file 3: Brain neocortical and hippocampal region size.
Graphs show that there are no significant differences detectable between
measured region sizes, thus the model does not suffer from atrophy within
the scope of the used n and natural variance in neither the neocortex nor
the hippocampus during the investigated range of age. It furthermore
excludes relevant bias in sample processing.
Additional file 4: Aβ concentrations in cortical brain homogenates
of APPSL transgenic mice over age. Aβ38 (A, D); Aβ40 (B, E), and Aβ42
(C, F) concentrations are shown in pg/mg cortical homogenates for
soluble (DEA; A-C) and insoluble (FA; D-F) fractions of 6, 9, and 12 month
old APPSL mice. N = 10 per group. All data were analyzed by two way
ANOVA followed by Bonferroni’s post hoc test. * significances between
genotypes. + significances between age groups of APPSL transgenic mice.
*P <0.05; **P <0.01; ***P <0.001. ### significances between six-month-old
APPSL and non-transgenic littermates as analyzed by t-test (P <0.001).
Analysis of the FA fraction of nine month old APPSL mice for Aβ42 was
not possible due to technical problems.
Additional file 5: LOC in non-transgenic APPSL littermates.
Representative images of an nTg littermate control animal at 12 months
of age. Inlets show a piece of the neocortex (Cx) and the hippocampal
subiculum (HC). Note that nTg do not show any kind of LOC labelling.
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